{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:04:49Z","timestamp":1759017889579,"version":"3.44.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.clinthera.2020.07.010","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T22:14:27Z","timestamp":1597270467000},"page":"1778-1786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of Food on the Pharmacokinetic Properties of Surufatinib: A Phase I, Single-dose, Randomized, Open-label Crossover Study in Healthy Subjects"],"prefix":"10.1016","volume":"42","author":[{"given":"Hongjie","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingying","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2724-3737","authenticated-orcid":false,"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4054-5243","authenticated-orcid":false,"given":"Yang","family":"Sai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiguo","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.07.010_bib1","doi-asserted-by":"crossref","first-page":"R453","DOI":"10.1530\/ERC-17-0531","article-title":"Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms","volume":"25","author":"Grillo","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clinthera.2020.07.010_bib2","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-06-1520","article-title":"Vascular endothelial growth factor signaling pathways: therapeutic perspective","volume":"12","author":"Kowanetz","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2020.07.010_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11912-012-0225-0","article-title":"FGF receptor inhibitors: role in cancer therapy","volume":"14","author":"Daniele","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clinthera.2020.07.010_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.clinthera.2020.07.010_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00018-005-5426-3","article-title":"The role of VEGF receptors in angiogenesis; complex partnerships","volume":"63","author":"C\u00e9be-Suarez","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clinthera.2020.07.010_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175563","article-title":"Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes","volume":"12","author":"Burmeister","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2020.07.010_bib7","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clinthera.2020.07.010_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.seminoncol.2006.04.005","article-title":"New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors","volume":"33","author":"Faivre","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinthera.2020.07.010_bib9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/17425255.2019.1700951","article-title":"Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors","volume":"15","author":"Fazio","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2020.07.010_bib10","doi-asserted-by":"crossref","first-page":"42076","DOI":"10.18632\/oncotarget.14942","article-title":"Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clinthera.2020.07.010_bib11","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1158\/1078-0432.CCR-18-2994","article-title":"Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, single-arm, open-label, Phase Ib\/II trial","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2020.07.010_bib12","article-title":"Absorption, metabolism and excretion of surufatinib in rats and humans","author":"Li","year":"2020","journal-title":"Curr Drug Metab"},{"journal-title":"Drug Rev Cent China Food Drug Adm","article-title":"Principles of technical guidance on bioavailability and bioequivalence study in humans for chemical drug preparations","year":"2007","key":"10.1016\/j.clinthera.2020.07.010_bib13"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820303441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820303441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:56Z","timestamp":1758963176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820303441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0149291820303441"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.07.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Food on the Pharmacokinetic Properties of Surufatinib: A Phase I, Single-dose, Randomized, Open-label Crossover Study in Healthy Subjects","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}